央广网郑州6月27日消息（记者 郝振青）合规经营是企业发展的生命线。在河南省郑州经济技术开发 区，郑州安图生物工程股份有限公司（以下简称 "安图生物"）将"合规"植入进研发、生产、销售乃至 财务管理的每一个环节，实现从票据审核、费用报销到税务申报的全链条智能管控。 全链合规管控：助力企业高质量发展 "我们公司新人入职的'第一课'，便是通过模拟真实业务场景的报销流程实训、票据合规性实战演练， 让'合规意识'如同基因般融入每位员工的职业血脉。"安图生物相关负责人说，该公司的管理层将合规 决策纳入日常管理，每月召开的"合规决策情景模拟"，使每个流程都嵌入合规责任清单，让税务合规从 财务部门的"独角戏"变为全公司的"大合唱"。 作为体外诊断行业领军企业，安图生物始终将供应商合规管理视为激活产业链高质量发展的核心引擎。 从供应商的资质准入、纳税信用审查，到生产运营、质量管控等综合维度，安图生物均设置了严苛的筛 选标准。凭借这套科学严谨的体系，安图生物不仅保障了自身供应链的安全稳定，更通过 "以点带面" 的方式，引导上下游企业共同增强合规意识。 "严格的供应商信用管理既是供应链保障，更是行业合规发展的引擎。"安图生物采购 ...

Core Viewpoint - Antu Biology's investment dispute with Mobidiag has concluded with a settlement agreement, leading to the dissolution of their joint venture, Antu Mobidiag [1][3]. Group 1: Investment History - In December 2018, Antu Biology signed a joint venture agreement with Mobidiag to establish a company in China, with Antu investing €8 million for a 65% stake and Mobidiag investing €4.3 million for a 35% stake [1]. - Antu Mobidiag was primarily engaged in the research, sales, and after-sales services of molecular diagnostic products [1]. Group 2: Arbitration Process - In April 2024, Antu Biology filed for arbitration with the ICC due to disagreements over the joint venture and licensing agreements, following Mobidiag's unilateral termination of the agreements in November 2021 [2]. - The arbitration case was settled amicably before a hearing, resulting in a settlement agreement where Mobidiag will pay Antu Biology $10 million [3]. Group 3: Financial Performance - Antu Biology reported a revenue of 4.471 billion yuan for 2024, a year-on-year increase of 27.5468 million yuan, representing a growth of 0.62% [3]. - The net profit attributable to the parent company was 1.194 billion yuan, a decrease of 22.987 million yuan, reflecting a decline of 1.89% compared to the previous year [3]. - Antu Mobidiag has been operating at a loss, with net profits of -44.9566 million yuan for 2024 and -3.291 million yuan for the first quarter of 2025 [4]. Group 4: Impact of Dissolution - The dissolution of Antu Mobidiag is in accordance with the settlement agreement and will not materially affect Antu Biology's overall business development or profitability [4].

将投中网设为"星标⭐"，第一时间收获最新推送 这家公司累计拿到上亿美元融资。 作者丨 鲁智高 直到 2016 年，两人都在考虑做新的事情，同时对基因测序产生浓厚兴趣。意识到测序仪器决定着行业发展方向，而其中最 核心的器件是测序芯片，于是他们决定利用在芯片上的优势，把这个消费级的产品直接带到基因测序行业，从而在美国硅谷 成立了安序源。 考虑到中国在产品研发和审批上比美国更有优势，同时市场潜力和应用范围更大，以及产品放量的程度和速度也超过美国市 场，他们不久后便将公司落在商业化、市场化和国际化程度很高的深圳，同时团队还获得了当地包括住房补贴等人才计划的 支持。 来源丨 投中网 先是在美国创立，然后到中国发展，这家无锡明星公司如今又朝港股冲去。 近日，生物科技公司安序源申请在港上市。在两位博士的带领下，他们通过开发新一代电化学检测平台，已经研发出一款微 阵列芯片分析仪、两款 EL-NGS 基因测序仪，以及多种配套检测试剂盒。 一路走来，安序源获得真格基金、松禾资本、力合科创、华润创新股权投资基金、阿斯利康中金医疗产业基金、云锋基金、 康桥资本、国投招商、五源资本、和玉资本、元禾璞华、凯泰资本、聚明创投等支持，估值也 ...

证券代码：002022 证券简称：科华生物 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 投资者关系活动记录表 编号：2025001 | | □ 特定对象调研 □ 分析师会议 | | --- | --- | | 投资者关系活动 | □ 媒体采访 ☑ 业绩说明会 | | 类别 | □ 新闻发布会 □ 路演活动 | | | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 线上参与公司 2024 年度网上业绩说明会的投资者 | | 人员姓名 | | | 时间 | 2025 年 5 月 8 日下午 15:00-17:00 | | 地点 | 公司通过价值在线平台（www.ir-online.cn）举行 2024 年度业 | | | 绩说明会 | | 上市公司接待人 | 董事长、总裁李明先生，独立董事郑传芳先生，董事、副总裁、 | | 员姓名 | 董事会秘书金红英女士，财务总监罗芳女士 | | | 公司就投资者在 2024 年度业绩说明会中提出的问题进行了 回复： | | | 1、董事长，您好，面对营收和毛利下降，净利润持续亏损 | | | 的局面， ...

Core Viewpoint - Axbio International Limited, a biotechnology company focused on integrated circuit technology, has filed for an IPO on the Hong Kong Stock Exchange, despite reporting consecutive losses over the past two years and not generating revenue from its research products [1][2]. Company Overview - Axbio International Limited was established in 2016 and specializes in molecular diagnostic products, a next-generation electrochemical long-read sequencing platform (EL-NGS), and biochips, along with related services [2]. - The company's product pipeline includes a microarray chip analyzer, two EL-NGS gene sequencers, and various testing kits [4]. Financial Performance - The company reported no revenue in 2023, with projected revenue of $47,900 in 2024, primarily from the sale of AxiLona AXP-100 for research purposes [4]. - Financial data for 2023 and 2024 shows: - Revenue: $479,000 in 2024 - Cost of Sales: $175,000 in 2024 - Gross Profit: $304,000 in 2024 - Other Income: $1,935,000 in 2023 and $2,063,000 in 2024 - Total Loss: $22,856,000 in 2023 and $23,466,000 in 2024 [5]. - The losses are primarily attributed to research and administrative expenses, with R&D expenditures of $15.3 million in 2023 and $11.4 million in 2024 [6]. Shareholding and Investment - The company was founded by Dr. Hui Tian and Dr. Igor Ivanov, with Dr. Tian holding 30.44% of the shares, making him the largest single shareholder [7]. - Axbio has received investments from notable institutions including AstraZeneca, CICC, and Yunfeng Capital [9]. Use of IPO Proceeds - The funds raised from the IPO will be allocated for the further development, commercialization, and production of core products AxiLona EL-100 and AxiLona AXP-100, as well as the development of AxiLona AXP-1000 and other pipeline products [9].

现场对接，为宠物行业企业找市场 一批宠物行业优质企业参与了本次供需对接会。 4月28日，宝龙"有商机"暨萌宠产业供需对接会在龙岗区宝龙企业服务中心举办。本次活动聚焦政策解 读、跨境资源推介、产品路演、供需对接、场景推介等主题，吸引30余家宠物产品相关企业参加。 据了解，宝龙街道目前已集聚喂养、器具、用品、医疗等宠物产业链的一批优秀企业。2025年，宝龙结 合"有商机""有意思"工作部署，将在街道谋划一批宠物新业态、宠物IP，友好空间，积极推动产业与文 化、生活相融合。 政策护航，助力宠物产业跨境出海 市市场监督管理局龙岗监管局相关负责人介绍，2024年中国城镇犬猫消费市场规模达3002亿元。深圳 2024年全市宠物产业产值约100亿元，主要集中在宠物医疗、智能用品等领域，2027年预计将突破200亿 元。近期，全市的宠物产业扶持政策正在广泛征求意见，未来将在企业认定、研发投入、金融服务、人 才培养等方面给予宠物产品企业支持。龙岗区高度重视宠物经济潜力，通过精准送政策、举办消费活 动、建设22个宠物友好空间等举措助力产业发展。 本次供需对接会，龙岗区商务局相关负责人对龙岗区宠物产业和跨境电商产业进行了介绍。据了 ...

Core Insights - The company reported a revenue of 4.471 billion yuan for 2024, showing a year-on-year increase of 0.62%, while the net profit attributable to shareholders was 1.194 billion yuan, reflecting a decrease of 1.89% year-on-year [1] - The company's Q4 2024 revenue was 1.091 billion yuan, down 9.16% year-on-year, with a net profit of 238 million yuan, down 24.72% year-on-year [1] - For Q1 2025, the company achieved a revenue of 996 million yuan, a decrease of 8.56% year-on-year, and a net profit of 270 million yuan, down 16.76% year-on-year [1] Business Performance - The immunodiagnostics business remained stable, with significant growth in the molecular diagnostics segment and overseas operations. In 2024, immunodiagnostics revenue reached 2.556 billion yuan, up 2.9%, while molecular diagnostics revenue surged by 101% to 35 million yuan [2] - The overall revenue from domestic operations was 4.105 billion yuan, down 1.3%, but the gross margin improved to 68.64%, an increase of 1.43 percentage points, driven by the growth in molecular diagnostics and high-end equipment installations [2] - The overseas market saw a revenue increase of 36.25%, reaching 284 million yuan, as the company accelerated its global expansion [2] R&D and Product Development - The company invested 732 million yuan in R&D in 2024, accounting for 16.37% of its revenue, focusing on new product registrations and upgrading product structures [3] - New product registrations included 144 items, expanding the antibody detection series to 33 items covering six major disease categories [3] - The company launched several new instruments, including the AutoChem B2000 and B800 series, and advanced mass spectrometry systems, enhancing its high-end product matrix [3] Future Outlook - Revenue projections for 2025-2027 are estimated at 4.604 billion, 5.068 billion, and 5.559 billion yuan, with year-on-year growth rates of 2.96%, 10.09%, and 9.68% respectively [4] - Net profit forecasts for the same period are 1.261 billion, 1.421 billion, and 1.597 billion yuan, with growth rates of 5.60%, 12.63%, and 12.43% respectively [4] - The current price-to-earnings ratio is projected to be 18, 16, and 14 times for the years 2025, 2026, and 2027 respectively [4]